New Pneumococcal Vaccine CAPVAXIVE Approved by FDA

The U.S. Food and Drug Administration has approved CAPVAXIVE for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae in individuals 18 years of age and older.